Philip Morris International reported strong second-quarter 2026 results with year-on-year growth in both revenue and net income, while its affiliate Swedish Match USA received FDA Marketing Granted Orders for 11 ZYN ULTRA moist oral nicotine pouch products, including all 9mg variants and one 11mg variant. The FDA's July 2026 decision to renew Modified Risk Tobacco Product orders for ZYN and certain IQOS devices further expands PMI's portfolio of FDA-sanctioned reduced-exposure offerings. The company's narrative projects $49.8 billion revenue and $15.5 billion earnings by 2029, requiring 5.4% yearly revenue growth and a $4.7 billion earnings increase from $10.8 billion. Some bearish analysts had assumed only about 4.8% annual revenue growth to roughly $48.9 billion by 2029, and their more pessimistic view on tougher regulation and slower smoke-free adoption may need updating after the latest ZYN ULTRA news.
Philip Morris International IncFDA granted marketing orders for ZYN ULTRA and renewed MRTP orders, expanding approved reduced-exposure products.
